ArticleMalaria journal2017
Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles.
Article in Malaria journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Systematic review of Anopheles abundance and meta-analysis of nonhuman primate malaria infection in mosquitoes in Thailand.Parasites & vectors · 2026Pooled it
- Ivermectin treatment in humans for reducing malaria transmission.The Cochrane database of systematic reviews · 2021Pooled it
- Measuring effects of ivermectin-treated cattle on potential malaria vectors in Vietnam: A cluster-randomized trial.PLoS neglected tropical diseases · 2024Trial
- Trial
- Identification of the metabolites of ivermectin in humans.Pharmacology research & perspectives · 2021Trial
- A dynamic pharmacometric framework defining the relationship between ivermectin exposure and mosquito lethality.Scientific reports · 2026Article
- Toxicity of ivermectin on multiple insecticide-resistant populations of Anopheles gambiae sensu lato, Aedes aegypti, and Culex mosquitoes.Parasites & vectors · 2026Article
- Article
- Optimizing endectocide and ectocide compound evaluation in Anopheles malaria vectors.Parasites & vectors · 2025Article
- Comparative susceptibility of wild and laboratory-reared Aedes and Anopheles larvae to ivermectin.Malaria journal · 2025Article
- Impact of standard and long-lasting ivermectin formulations in cattle and buffalo on wild Anopheles survival on Sumba Island, Indonesia.Scientific reports · 2024Article
- The antiviral JNJ-A07 significantly reduces dengue virus transmission byScience advances · 2024Article
- Antiplasmodial and Insecticidal Activities of Third-Generation Ivermectin Hybrids.Journal of medicinal chemistry · 2024Article
- Efficacy of ivermectin and its metabolites againstAntimicrobial agents and chemotherapy · 2024Article
- Impact ofInsects · 2024Article
- Cytotoxic effects of ivermectin onFrontiers in microbiology · 2024Article
- Article
- Revolutionizing Malaria Vector Control: The Importance of Accurate Species Identification through Enhanced Molecular Capacity.Microorganisms · 2023Review
- Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania.CPT: pharmacometrics & systems pharmacology · 2023Article
- A field bioassay for assessing ivermectin bio-efficacy in wild malaria vectors.Malaria journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundNovel vector control methods that can directly target outdoor malaria transmission are urgently needed in the Greater Mekong Subregion (GMS) to accelerate malaria elimination and artemisinin resistance containment efforts. Ivermectin mass drug administration (MDA) to humans has been shown to effectively kill wild Anopheles and suppress malaria transmission in West Africa. Preliminary laboratory investigations were performed to determine ivermectin susceptibility and sporontocidal effect in GMS Anopheles malaria vectors coupled with pharmacokinetic models of ivermectin at escalating doses.
methodsA population-based pharmacokinetic model of ivermectin was developed using pre-existing data from a clinical trial conducted in Thai volunteers at the 200 µg/kg dose. To assess ivermectin susceptibility, various concentrations of ivermectin compound were mixed in human blood meals and blood-fed to Anopheles dirus, Anopheles minimus, Anopheles sawadwongporni, and Anopheles campestris. Mosquito survival was monitored daily for 7 days and a non-linear mixed effects model with probit analyses was used to calculate concentrations of ivermectin that killed 50% (LC
resultsThe GMS Anopheles displayed a range of susceptibility to ivermectin with species listed from most to least susceptible being An. minimus (LC
conclusionsIvermectin is lethal to dominant GMS Anopheles malaria vectors and inhibits sporogony of P. vivax at safe human relevant concentrations. The data suggest that ivermectin MDA has potential in the GMS as a vector and transmission blocking control tool to aid malaria elimination efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.